FDA-Approved Therapy
UPMC Hillman Cancer Center currently offers all FDA-approved CAR T-cell therapies.
Learn MoreUPMC Hillman Cancer Center is part of the UPMC family.
Explore this Section
Chimeric antigen receptor (CAR) T-cell therapy uses a person's own T cells to find and kill cancer cells.
UPMC Hillman Cancer Center was one of the first centers in the U.S. to offer CAR T-cell immunotherapy.
UPMC also tests new forms of this cutting-edge cancer treatment through clinical trials.
To learn if a CAR-T cell clinical trial is right for you, call 1-833-876-2227.
A T cell is a type of white blood cell that fights infection and disease. When a T cell sees a threat — like a virus-infected cell — it kills that cell to protect the body.
The goal of CAR T-cell therapy is to make T cells attack cancer cells instead of just infected cells.
First, doctors harvest a person's T cells and send them to a special lab. The lab genetically alters the cells to spot a certain protein in cancer cells. They then grow large numbers of the altered T cells.
After a few weeks in the lab, the CAR T cells will be ready for infusion.
Once the CAR T cells return to UPMC, our team puts them back into the person. The CAR T cells then attack and kill cancer cells as they were “trained."
CAR T-cell therapy is challenging to provide, so few hospitals can offer this potentially lifesaving treatment.
UPMC Hillman Cancer Center:
To refer a patient for evaluation for one of these clinical trials, please call 1-833-876-2227.
If you think you might be a candidate for one of these clinical trials, please call 1-833-876-2227.
FDA-Approved Therapy
UPMC Hillman Cancer Center currently offers all FDA-approved CAR T-cell therapies.
Learn MoreResearch and Clinical Trials
UPMC Hillman Cancer Center is currently enrolling patients in CAR T-cell therapy clinical trials.
Learn More